Mirna Therapeutics has appointed a number of new board members following its recent Series C financing round (see related story, this issue).
Joining the board are Michael Powell, a general partner at Sofinnova Ventures, and Ed Mathers, a partner at New Enterprise Associates.
New additions to the board of directors also include Elaine Jones, executive director for venture capital/worldwide business development at Pfizer.
Silence Therapeutics has named Tim Freeborn as its finance director.
Freeborn joins Silence from Xcap Securities, where he was head of research.